Joan Seoane Vall d’Hebron Institute of Oncology (VHIO)
Vall d’Hebron University Hospital Barcelona
Vall d'Hebron
Hospital General
Everything you always wanted to know about creating a company
(but were afraid to ask)
• Cytokine of the IL6 family
• Crucial for embryonic stem cells
• Crucial for embryo implantation
• Induces neural stem cell self-renewal
• Induces glial differentiation
• Role in immune system
Leukemia Inhibitory Factor (LIF)
LIF
Stat3
Stat3
JAK
LIFR GP130
PBS
Anti-
LIF D
30
10
20
30 * p=0.0175
0 10 20 300
5
10
15
Control
MSC-1
Days after
cell inoculation
MSC-1 (15mg/kg)
Control MSC-1
Tu
mo
r V
olu
me
(Flu
x [
p/s
] fo
ld i
ncre
ase)
MSC-1 Promotes Tumor Regression
Radia
nce
(p/s
ec/c
m2/s
r)
• LIF KO mice are viable but infertile (no implantation of blastocysts)1
• Women with mutations in LIF gene are healthy although infertile
1 Stewart et al. Nature 1992; 359: 76-9; Escary et al. Nature 1993; 363: 361-4; Chen et al. Endocrinology
2000; 141: 4365-72.
Toxicity
Josep Baselga, MD, PhD
Chair SAB, co-founder
Joan Seoane, PhD
Chairman, co-founder
Judit Anido, PhD, MBA
CEO, co-founder
Frank McCormick, PhD, FRS Co-Chair of the SAB
David A. Wood Distinguished
Professor of Tumor Biology and
Cancer Research at the UCSF
School of Medicine.
Previously was the Founder and
CSO at Onyx Pharmaceuticals.
He also served as VP of
Research at Chiron Corporation
and Cetus Corporation.
Mosaic’s Team
Scientific Advisors
Mosaic’s Team
Investors
Guido Magni, MD, PhD
Member of the BoD
Gianni Gromo, MD, PhD
Member of the BoD
Partner at Versant Ventures.
Previously served as a Senior
Executive at Roche including
Research Head of Global
Cardiovascular and Metabolic
Research, Head of Discovery
Research (Basel site), Global Head
of the Metabolic and Vascular
Disease Business Unit, and Head of
the Roche China R&D center.
Partner at Versant Ventures.
Previously served as Managing
Director of EuroVentures, a
Versant incubator and Global
Head of the Medical Science
Department of Roche
Pharmaceuticals. Among others
oversaw the development and
the registration Mabthera,
Xeloda, Herceptin and Tarceva.
Mosaic’s Team
Consultants Kent Iverson - Manufacturing - San Francisco, California, US 18 years experience in manufacturing including Genentech (Protropin™, Activase™); Immunex (9 years, Leukine™, Enbrel™);
Coulter (Bexxar-radiolabeled antibody for cancer treatment) and Corixa (VP of Process Development). Current advisor at Lonza.
Claire Barton - Clinical Development - London, UK Medical oncologist/pharmaceutical physician specializing in the clinical development of products for oncology indications.
Former positions at Roche Products Ltd (Clinical Science Leader for Herceptin); Eli Lilly and Co. Ltd (European Clinical
Development Physician) and Glaxo Wellcome.
Karin Jorga - Clinical Development - Basel, Switzerland More than 20 years experience at Roche in transitioning pre-clinical lead molecules to Clinical Proof-of-Concept and advancing
novel biomarkers to drive Personalized Healthcare of small and large molecules across all therapeutic areas.
Jennifer Sims - Pre-clinical and Tox Development - Basel, Switzerland European Registered Toxicologist with 15 years experience in preclinical drug development including non-clinical
pharmacology, translational PK-PD and safety assessment for new medicinal products. Former positions at Novartis (Head of
Translational Sciences & Safety) and Astra Zeneca/MedImmune (Global Head Biopharma Safety Assessment)
NDA REG - Regulatory Drug Development - Zurich, Switzerland Paul Chamberlain: 35 years of experience. Specialized on the design of IND enabling packages for antibodies for
oncology.
Klass Zuideveld - Companion Diagnostic Development - Basel, Switzerland 14 years experience in the development of companion diagnostics. Former positions at Hoffmann-La Roche Ltd Pharma
(Product Optimization Leader); F. Hoffmann-La Roche Ltd. Diagnostics Providing strategic support to the Diagnostics COO and
at Roche NimbleGen as a Director of Personalized Healthcare among others.
Len Presta- Antibody Engineering- Palo Alto, California, US 30 years of experience in protein/antibody engineering. At Genentech: responsible for the protein engineering that led to
marketed therapeutic monoclonal antibodies Herceptin, Raptiva, Xolair, Avastin, Lucentis, Perjeta and therapeutic protein
Tenecteplase. At Merck (formerly Schering-Plough, DNAX): responsible for protein and antibody engineering of internal
therapeutic antibodies in the pipeline.
VALUE CREATION
Stage: Pre-clinical
Stage: Phase I/II Clinical trial
Business strategy
Stage: Compound development Regulatory toxicology